share_log

First Wave BioPharma Announced Expansion of Adrulipase Intellectual Property Portfolio

Benzinga Real-time News ·  Jan 25, 2023 07:08

First Wave BioPharma, Inc. (NASDAQ:FWBI) announced today the company has filed a U.S. Provisional Patent application involving composition of matter improvements designed to enhance adrulipase's delayed release profile. This filing adds to the growing intellectual property (IP) portfolio governing adrulipase, which includes patent applications governing adrulipase formulation and methods of use and the utilization of enteric formulations in the delivery of adrulipase.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment